Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Robert Spiera,Masataka Kuwana,Dinesh Khanna, Laura M. Hummers,Tracy Frech,Wendy Stevens,Marco Matucci-Cerinic,Suzanne Kafaja,Oliver Distler,Jae-Bum Jun,Yair Levy,Piotr Leszcyznski,Jessica Gordon,Virginia Steen,Eun Bong Lee,Tomasz Jankowski,Irena Litinsky,Lorina Chung,Vivien Hsu,Maureen Mayes,Nora W. Sandorfi,Robert Simms,Stephanie Finzel,Jeska de Vries-Bouwstra,Scott Constantine,Nancy Dgetluck,Quinn J. Dinh, Bradley E. Bloom,Daniel Furst,Barbara P. White,Christopher Denton ARTHRITIS & RHEUMATOLOGY（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper